S&P 500 falls on pressure from retail stocks, weak jobless claims
In a recent transaction, John T. Treace, the Chief Executive Officer of Treace Medical (TASE:BLWV) Concepts, Inc. (NASDAQ:TMCI), purchased a significant amount of company stock. According to the SEC filing, Treace acquired 60,000 shares of common stock on March 4, 2025, at a weighted average price of $8.7344 per share, totaling approximately $524,064. The purchase comes as InvestingPro data shows the stock has experienced an 8% decline over the past week, though it maintains a impressive 55% gain over the last six months.
Following this acquisition, Treace now directly owns 6,796,190 shares. Additionally, he has indirect ownership over a substantial number of shares held by his spouse and in various trusts, although he disclaims beneficial ownership of these indirectly held shares. This purchase reflects Treace’s continued confidence in the company’s prospects and aligns with his role as a key executive and major shareholder. According to InvestingPro analysis, analysts have set price targets ranging from $9 to $16, suggesting potential upside from current levels. Get deeper insights into TMCI’s valuation and 7+ additional ProTips with an InvestingPro subscription, including access to comprehensive Pro Research Reports covering 1,400+ US stocks.
In other recent news, Treace Medical Concepts Inc. reported its fourth-quarter 2024 earnings, surpassing expectations with a loss of $0.01 per share, compared to the forecasted loss of $0.04. The company’s revenue reached $68.7 million, exceeding the anticipated $67.02 million, marking a 10.4% growth year-over-year. Despite these positive results, the company’s stock experienced a decline in aftermarket trading. Looking ahead, Treace Medical has set its 2025 revenue guidance between $224 million and $230 million, indicating a growth rate of 7-10%. The company aims for breakeven adjusted EBITDA by the end of 2025. In other developments, Stifel analysts maintained a Hold rating on Treace Medical with a price target of $9.00, following discussions with the company’s executives about strategic product rollouts and financial outlook for 2025. New product introductions, including Nanoplasty/Percuplasty and SpeedMTP/SpeedAkin, are expected to drive growth in the latter half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.